{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:23:47Z","timestamp":1773833027582,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T00:00:00Z","timestamp":1530576000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12882-018-0958-6","type":"journal-article","created":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T04:59:47Z","timestamp":1530593987000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Minimal change disease associated with anti-PD1 immunotherapy: a case report"],"prefix":"10.1186","volume":"19","author":[{"given":"Bixia","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningjing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8826-7911","authenticated-orcid":false,"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,3]]},"reference":[{"issue":"19","key":"958_CR1","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803\u201313.","journal-title":"N Engl J Med"},{"issue":"4","key":"958_CR2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372(4):311\u20139.","journal-title":"N Engl J Med"},{"key":"958_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","volume":"45","author":"TK Eigentler","year":"2016","unstructured":"Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Grunwald V, Kahler KC, Loquai C, Reinmuth N, Steins M, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev. 2016;45:7\u201318.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"958_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/PPO.0000000000000296","volume":"24","author":"DY Wang","year":"2018","unstructured":"Wang DY, Johnson DB, Davis EJ. Toxicities associated with PD-1\/PD-L1 blockade. Cancer J. 2018;24(1):36\u201340.","journal-title":"Cancer J"},{"issue":"3","key":"958_CR5","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","volume":"90","author":"FB Cortazar","year":"2016","unstructured":"Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP, Brahmer JR, Le DT, Lipson EJ, Glezerman IG, Wolchok J, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90(3):638\u201347.","journal-title":"Kidney Int"},{"issue":"3","key":"958_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/ckj\/sfw024","volume":"9","author":"N Murakami","year":"2016","unstructured":"Murakami N, Borges TJ, Yamashita M, Riella LV. Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. Clin Kidney J. 2016;9(3):411\u20137.","journal-title":"Clin Kidney J"},{"issue":"12","key":"958_CR7","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1038\/bjc.2016.358","volume":"115","author":"J Belliere","year":"2016","unstructured":"Belliere J, Meyer N, Mazieres J, Ollier S, Boulinguez S, Delas A, Ribes D, Faguer S. Acute interstitial nephritis related to immune checkpoint inhibitors. Br J Cancer. 2016;115(12):1457\u201361.","journal-title":"Br J Cancer"},{"issue":"3","key":"958_CR8","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.kint.2015.11.028","volume":"89","author":"JM Kidd","year":"2016","unstructured":"Kidd JM, Gizaw AB. Ipilimumab-associated minimal-change disease. Kidney Int. 2016;89(3):720.","journal-title":"Kidney Int"},{"issue":"4","key":"958_CR9","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1053\/j.ajkd.2017.04.026","volume":"70","author":"A Kitchlu","year":"2017","unstructured":"Kitchlu A, Fingrut W, Avila-Casado C, Chan CT, Crump M, Hogg D, Reich HN. Nephrotic syndrome with cancer immunotherapies: a report of 2 cases. Am J Kidney Dis. 2017;70(4):581\u20135.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"958_CR10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/0002-9343(71)90205-1","volume":"50","author":"J Plager","year":"1971","unstructured":"Plager J, Stutzman L. Acute nephrotic syndrome as a manifestation of active Hodgkin\u2019s disease. Report of four cases and review of the literature. Am J Med. 1971;50(1):56\u201366.","journal-title":"Am J Med"},{"issue":"3","key":"958_CR11","first-page":"114","volume":"24","author":"P Kramer","year":"1981","unstructured":"Kramer P, Sizoo W, Twiss EE. Nephrotic syndrome in Hodgkin's disease. Report of five cases and review of the literature. Neth J Med. 1981;24(3):114\u20139.","journal-title":"Neth J Med"},{"issue":"12","key":"958_CR12","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1038\/sj.ki.5000341","volume":"69","author":"V Audard","year":"2006","unstructured":"Audard V, Larousserie F, Grimbert P, Abtahi M, Sotto JJ, Delmer A, Boue F, Nochy D, Brousse N, Delarue R, et al. Minimal change nephrotic syndrome and classical Hodgkin\u2019s lymphoma: report of 21 cases and review of the literature. Kidney Int. 2006;69(12):2251\u201360.","journal-title":"Kidney Int"},{"issue":"8","key":"958_CR13","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1002\/1097-0142(19850415)55:8<1799::AID-CNCR2820550827>3.0.CO;2-S","volume":"55","author":"CM Shapiro","year":"1985","unstructured":"Shapiro CM, Vander Laan BF, Jao W, Sloan DE. Nephrotic syndrome in two patients with cured Hodgkin's disease. Cancer. 1985;55(8):1799\u2013804.","journal-title":"Cancer"},{"issue":"3","key":"958_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/ndt\/6.3.155","volume":"6","author":"R Peces","year":"1991","unstructured":"Peces R, Sanchez L, Gorostidi M, Alvarez J. Minimal change nephrotic syndrome associated with Hodgkin's lymphoma. Nephrol Dial Transplant. 1991;6(3):155\u20138.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"958_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","volume":"11","author":"H Nishimura","year":"1999","unstructured":"Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141\u201351.","journal-title":"Immunity"},{"issue":"7","key":"958_CR16","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/sj.ki.5000345","volume":"70","author":"XH Qin","year":"2006","unstructured":"Qin XH, Lee VW, Wang YP, Zheng GP, Wang Y, Alexander SI, Harris DC. A protective role for programmed death 1 in progression of murine adriamycin nephropathy. Kidney Int. 2006;70(7):1244\u201350.","journal-title":"Kidney Int"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-0958-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-018-0958-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-0958-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T19:11:25Z","timestamp":1562094685000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-018-0958-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,3]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["958"],"URL":"https:\/\/doi.org\/10.1186\/s12882-018-0958-6","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,3]]},"assertion":[{"value":"9 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"According to the Declaration of Helsinki revised in 2004 and to the rules of the Ethical committee of the First Hospital of Peking University, the study was formally approved by the Ethical committee for the collection and publication of the patient\u2019s information. And the patient was also informed of the collection of his clinical data and gave informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"156"}}